Home » Newsletters » BioWorld Science

BioWorld Science

July 28, 2003

View Archived Issues

Spotlight on viral enzyme inhibitors for the treatment of chronic hepatitis B

Olprinone reduces gut mucosal injury in rabbit model of hypoxia

E-7389 analogues designed to have minimal susceptibility to P-glycoprotein-mediated drug efflux

FR-901228 induces apoptosis in primary and metastatic uveal melanoma cell lines

U. of Minnesota scientists claim new cADPR analogues for use as immunostimulants

AstraZeneca presents new MEK inhibitors in a recent patent

IOP-lowering agents prepared and tested by Alcon researchers

Novel lipase inhibitors for obesity and diabetes in early development at OSI

New NHE-3 inhibitors and their use in sleep apnea, renal failure, stroke, etc.

Taisho patents novel melanocortin MC4 receptor antagonists

Pfizer claims new 5-HT4 receptor modulators and their use in gastrointestinal disorders

Antitumor and antiinflammatory properties of synthetic triterpenoids under study at Dartmouth

Third-generation protease inhibitor active against wild-type and resistant HIV

Lead NPI-2350 (halimide) analogues with improved cytotoxic activity presented at AACR meeting

Preliminary 48-week data from CONTEXT study

CF-101 evaluated in new phase II trial for active RA

Pan-VEGFR tyrosine kinase inhibitor with antiangiogenic and antiproliferative activity

Phase II Canadian trial of MC-4232 cleared to begin

Positive phase II results for arginine deiminase in HCC support initiation of phase III trial

MBI-226 fails to meet primary endpoint in phase III trial

VNP-40101M in combination with AraC tested in new phase I trial for leukemia

La Jolla may seek accelerated approval for Riquent

Zyvox approved for diabetic foot infections

BTG licenses anxiety and depression compounds to Abiogen

FDA clears safinamide IND for Parkinson's disease

Enbrel becomes the first FDA-approved biologic for ankylosing spondylitis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.